The Republic of Ireland Invests in Pharmaceutical Manufacturing Technology Center
The University of Limerick will be the headquarters for a new $6.4-million research and innovation center.
The University of Limerick has announced the launch of the Pharmaceutical Manufacturing Technology Centre (PMTC) on Sept. 12, 2014, which will be headquartered at the University of Limerick. The Republic of Ireland’s Department of Jobs, Enterprise, and Innovation will invest $6.4 million into the center over the course of five years. PMTC will focus on innovation and manufacturing issues that threaten the Irish pharmaceutical industry, which contributes more than $51 billion in annual Irish exports per year.
PMTC is designed to support the Irish pharmaceutical industry, which employs more than 25,000 individuals, while working to make Ireland the global hub of pharmaceutical process innovation and manufacturing. PMTC is one of 15 state-supported technology centers established jointly by Enterprise Ireland and IDA Ireland. The center includes 24 industry partners and nine higher education institutes who will supply research.
Source: University of Limerick
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
